The clinical evaluation of pepsinogen, trypsinogen-2, CEA, CA50 and CA242 in gastric cancer diagnosis.

[Objective] To study the clinic value of pepsinogen (PG) I, PG II, tumor markers trypsinogen-2, CEA, CA50, CA242 in diagnosis of gastric cancer. [Methods] The levels of serum PGI, PGII, TAT2, CEA, CA50 and CA242 as well as PGI / PGII ratio were determined by time-resolved fluoroimmunoassay (TRFIA) in 116 patients with gastric cancer and 60 healthy volunteers. [Results] The sensitivity of PGI, PGI / PGII ratio, CEA, CA50, CA242 and TAT2 in diagnosis of gastric cancer was 34.48%, 38.79%, 12.93%, 13.79%, 26.72% and 27.59%, respectively, while the levels of them in tumor group were significantly different from those in control group. The parallel detection could improve the sensitivity of detection methods, and kept a high specificity (﹥80%) . The sensitivity of parallel detection of PGI, PGI / PGII ratio and TAT2 was 70.96%. If adding more tumor marker tests including CEA, CA50 or CA242, the sensitivity increased to 84.02%, and the positive likelihood ratio showed to be high, while the negative likelihood ratio presented to be low. [Conclusion] Combined determination of serum levels of PGI, PGI / PGII ratio, TAT2, CA242, CA50 and CEA in TRFIA with high throughout quality could obviously improve the detective rate of mass screening for gastric cancer.